Heart Test Laboratories announced that its European Patent Office, EPO, Application EP3834729 has been granted. Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are pleased to receive this latest patent grant which further reinforces our position at the forefront of AI-ECG. This patent is particularly valuable because it covers the use of AI-ECG to produce any echo measure of diastolic function, which is fundamental to screen for a broad range of heart disease at an early stage.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSCS:
- HeartSciences to Present at the LD Micro Invitational XIV Conference
- Heart Test Laboratories announces podium presentation on MyoVista wavECG
- HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
- Heart Test Laboratories price target lowered to 35c from $3 at Maxim
- HeartSciences Reports Third Quarter Fiscal 2024 Financial Results